Validation of BodPod in Pediatric Anorexia Nervosa

Overview

Anorexia nervosa is a severe cause of undernutrition. It leads to a dramatic decrease of weight with an important modification of the body composition. During the renutrition phase, disharmonious body composition recovery is a relapse factor. Dual X-ray absorptiometry (DXA) is the gold standard to study body composition in children with anorexia nervosa. But, due to technical limits, DXA analysis needs to take in account a potential failure to thrive with an adjustment on height. Moreover DXA needs an irradiation which does not allow close repeat measurements. Since several years, a simple, non-invasive, non-irradiant method for measure of body composition has been developed in pediatrics: the air displacement plethysmography (ADP). Actually, only one device is available for this measurement: the BodPod®. However, feasibility and accuracy of ADP compare to DXA have not been evaluated in pediatric anorexia nervosa. The aim of this study is to compare the accuracy of BodPod® compare to DXA in girls with anorexia nervosa.

Full Title of Study: “Accuracy of Air Displacement Plethysmography Compare to Dual X-ray Absorptiometry (DXA) in Girls With Anorexia Nervosa”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2024

Interventions

  • Other: Measure of body composition by Air Displacement Plethysmography (ADP)
    • Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.

Arms, Groups and Cohorts

  • Other: Undernourished Patients
    • All patients included will be included in the unique arm of the study

Clinical Trial Outcome Measures

Primary Measures

  • Accuracy of Air Displacement Plethysmography (ADP) for body fat mass measurement
    • Time Frame: 1 year
    • The accuracy of Air Displacement Plethysmography (ADP) will be compare to Dual X-ray Absorptiometry (DXA) according to the percentage of body fat mass measurement. The hypothesis will be validating if difference in percentage in body fat mass between ADP and DXA is below the 4%. The measurement will be done two times at 1 year interval

Secondary Measures

  • Acceptability of Air Displacement Plethysmography (ADP) by the patient compared to Dual X-ray Absorptiometry (DXA)
    • Time Frame: 1 year
    • The questionnaire includes 3 questions after the ADP using simple analog visual scales adapted to children comprehension. The measurement will be done two times at 1 year interval
  • Accuracy of Air Displacement Plethysmography (ADP) compare to Bio Electrical Impedance (BEI)
    • Time Frame: 1 year
    • The difference between percentage of body fat mass will quantified between ADP and BEI. The measurement will be done two times at 1 year interval
  • Longitudinal evolution of the percentage of body fat mass
    • Time Frame: 1 year
    • The evolution of the percentage of body fat mass will be evaluated after 1 year of evolution.

Participating in This Clinical Trial

Inclusion Criteria

  • Female patients aged between 8 and 18 years – Female with a diagnosis of anorexia nervosa according to the DSM V classification, restrictive type or hyperphagic / purgative access type, evolving for less than 3 years. – Female who received explanations adapted to their level of understanding for this study – Female who expressed their consent to participate to this study – Female whose parents or holders of parental authority have been informed and signed free and informed consent – Female affiliated to a social security scheme Exclusion Criteria:

  • Patients with psychotic symptoms – Patients with claustrophobia – Patients with severe respiratory disease

Gender Eligibility: Female

Minimum Age: 8 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Diane MORFIN, Dr, 04.27.85.60.11, diane.morfin@chu-lyon.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.